Lung Cancer, Lung Cancer Stage I
Conditions
Keywords
lung cancer, lung cancer stage 1, segmentectomy, Memorial Sloan Kettering Cancer Center, 24-127
Brief summary
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Interventions
Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology
Exclusion criteria
* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years * History of chemotherapy or radiation therapy for a previous lung cancer * Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery * Carcinoid tumors * History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix * Actively receiving treatment for other malignancies * Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis. * Multi-segmental resection from the same lobe is not a criterion for exclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer. | 3 years | DFS is measured from the date of surgery to the date of recurrence or death |
| Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer. | 5 years | DFS is measured from the date of surgery to the date of recurrence or death |
Countries
Canada, United States
Contacts
CONTACTDavid Jones, MD
CONTACTBernard Park, MD
PRINCIPAL_INVESTIGATORDavid Jones, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed